Congestive heart failure and arrhythmias: an overview.
Arrhythmias are common in patients with congestive heart failure (CHF), especially those with concomitant ischemic heart disease. The degree of left ventricular dysfunction is the most important indicator of prognosis in patients with severe heart failure. In general, the better the patient's ventricular function, the greater his chance of survival. In addition, the severity of arrhythmias is also related to survival; patients with simple arrhythmias have higher survival rates than those with complex arrhythmias. All drugs used in the treatment of CHF have a potential proarrhythmic effect. In a study involving the new class of positive inotropic agents, a trend toward higher mortality was evident in CHF patients with ischemic heart disease compared with those with congestive dilated cardiomyopathy. A subgroup of patients also treated with antiarrhythmic agents had lower sudden death rates than those not receiving antiarrhythmics. A double-blind clinical trial of antiarrhythmic agents for patients with CHF is warranted.
D001145:Arrhythmias, Cardiac / Q000209:etiology* / Q000401:mortality; D004077:Digoxin / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D005260:Female; D006333:Heart Failure / Q000150:complications*; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D011379:Prognosis; D012737:Sex Factors; D014665:Vasodilator Agents / Q000009:adverse effects
D004232:Diuretics; D014665:Vasodilator Agents; D004077:Digoxin